| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD (MFL and DSM); the Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston (MJS, WCW, and ELG); the Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston (MJS, GCC, WCW, and ELG); and the Department of Medical Epidemiology, Karolinska Institutet, Stockholm (KA)
2 Supported by research grants CA055075 and HL035464 from the National Institutes of Health (to WCW) and Cancer Epidemiology Training Grant 5T32 CA09001-26 (to MFL) from the National Cancer Institute. 3 Address reprint requests to MF Leitzmann, National Cancer Institute, 6120 Executive Boulevard, EPS-MSC 7232, Bethesda, MD 20892. E-mail: leitzmann{at}mail.nih.gov.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective: We prospectively evaluated the association between intakes of 
-linolenic (ALA; 18:3n–3), eicosapentaenoic (EPA; 20:5n–3), docosahexaenoic (DHA; 22:6n–3), linoleic (LA; 18:2n–6), and arachidonic (AA; 20:4n–6) acids and prostate cancer risk.
Design: A cohort of 47 866 US men aged 40–75 y with no cancer history in 1986 was followed for 14 y.
Results: During follow-up, 2965 new cases of total prostate cancer were ascertained, 448 of which were advanced prostate cancer. ALA intake was unrelated to the risk of total prostate cancer. In contrast, the multivariate relative risks (RRs) of advanced prostate cancer from comparisons of extreme quintiles of ALA from nonanimal sources and ALA from meat and dairy sources were 2.02 (95% CI: 1.35, 3.03) and 1.53 (0.88, 2.66), respectively. EPA and DHA intakes were related to lower prostate cancer risk. The multivariate RRs of total and advanced prostate cancer from comparisons of extreme quintiles of the combination of EPA and DHA were 0.89 (0.77, 1.04) and 0.74 (0.49, 1.08), respectively. LA and AA intakes were unrelated to the risk of prostate cancer. The multivariate RR of advanced prostate cancer from a comparison of extreme quintiles of the ratio of LA to ALA was 0.62 (0.45, 0.86).
Conclusions: Increased dietary intakes of ALA may increase the risk of advanced prostate cancer. In contrast, EPA and DHA intakes may reduce the risk of total and advanced prostate cancer.
Key Words: Diet • n–3 fatty acids • n–6 fatty acids • prostate cancer • cohort study
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-Linolenic acid (ALA; 18:3n–3) is the principal dietary n–3 fatty acid in most Western diets; it is present in some vegetable oils and nuts, leafy vegetables, and animal fats (3). ALA can serve in a limited capacity as a precursor for eicosapentaenoic acid (EPA; 20:5n–3) and docosahexaenoic acid (DHA; 22:6n–3) (4). The concentrations of EPA and DHA are high in fish oils and they consistently inhibit tumor cell growth in animal models and in cell lines from human prostate tumors (5). Linoleic acid (LA; 18:2n–6) is the most abundant n–6 fatty acid in the human diet, and it is found primarily in vegetable oils. Long-chain n–6 fatty acids enhance prostate tumor cell growth in human prostate tumor-derived cell lines (6). Several biological mechanisms have been proposed to explain these observations. Among the most salient of these mechanisms is the inhibition of eicosanoid biosynthesis by arachidonic acid (AA; 20:4n–6), an n–6 fatty acid derived from LA by the action of cyclooxygenase-2 (5). AA-derived eicosanoids, such as prostaglandin E2, strongly stimulate prostate tumor growth in animal models or prostate tumor-derived cell lines (7-9). In contrast, EPA and DHA inhibit cyclooxygenase-2 and the formation of prostaglandin E2 from AA (5). However, whether dietary n–3 and n–6 fatty acids and the ratio of these 2 classes of fatty acids affect the risk of prostate cancer in humans remains unclear (10).
In 1993, we reported on the association between dietary fat and risk of prostate cancer from a prospective study of male health professionals (11). The first study report was based on a single dietary assessment with follow-up from 1986 to 1990 and included 300 incident cases of prostate cancer. In that study, ALA was positively related to risk of advanced prostate cancer, whereas no association with prostate cancer was seen with n–3 fatty acids from fish and LA. More recently, with follow-up time through 1998 (2482 cases), we reported an inverse relation of fish and marine fatty acid intake with prostate cancer risk (12). The present analyses extend those findings to evaluate in detail the association between n–3 and n–6 fatty acids and prostate cancer based on repeated dietary assessments with follow-up from 1986 to 2000 and including 2965 incident cases of prostate cancer.
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Assessment of diet
Dietary intake was assessed in 1986, 1990, and 1994 by using a 131-item semiquantitative food-frequency questionnaire. To calculate intakes of nutrients and individual food items, a commonly used unit or portion size for each food (eg, one pat of margarine) was specified and the participants were asked to report how often, on average over the past year, they had consumed that amount. There were 9 possible response categories for each food item that ranged from never or less than once per month to 
6 times/d. The dietary questionnaire inquired specifically about the kind of fat usually used for frying, sautéing, and baking (vegetable oil, solid vegetable oil shortening, butter, margarine, lard, or none). In addition, we requested information on individual type and brand of cooking oil and margarine using one open-ended question each. We specifically queried about the frequency of intake of canned tuna, dark-meat fish (mackerel, salmon, sardines, bluefish, and swordfish), other fish (not specified), and shrimp, lobster, and scallops. We also inquired about the use of fish-oil supplements starting in 1988 (yes or no). Our assessment of fish-oil supplement use was expanded starting in 1990 (none, <2.5 g/d, 2.5–4.9 g/d, 5.0–9.9 g/d, and 10 g/d). This information was used to update exposure to EPA during follow-up.
Nutrient intakes were calculated for each participant by multiplying the frequency of consumption for each item by the nutrient content of the specified portion size. Food-composition data were primarily based on values obtained from the US Department of Agriculture but were supplemented with information from the manufacturers. We considered total ALA, ALA from meat and dairy sources, and ALA from nonanimal sources separately.
The validity and reproducibility of the food-frequency questionnaire were assessed by comparing nutrient intakes from two 1-wk diet records with those of the food-frequency questionnaire among a random sample of 127 Boston area participants. The correlation between energy-adjusted intake of polyunsaturated fat measured by diet records and by food-frequency questionnaire was 0.37 (13). The correlations between intakes of total polyunsaturated fat, LA, and EPA as a proportion of dietary fat and the proportion of fatty acids in adipose tissue samples were 0.50, 0.48, and 0.47, respectively (14).
Case ascertainment
On each follow-up questionnaire, we asked participants to report any diagnosis of prostate cancer during the previous 2 y. For men who reported prostate cancer (or next of kin for decedents), we requested permission to obtain their medical records and pathology reports to confirm the diagnosis and obtain further details. The response rate was >96%, and medical records and pathology reports were successfully obtained for 90% of the cases. The remaining cases included in the analysis were based on self-report. We included self-reports because the reporting of the diagnosis of prostate cancer was found to be highly accurate in these health professionals. A study physician who was unaware of the questionnaire data used the information received from any procedures or tests conducted during the initial diagnosis, including pathologic stage (or clinical stage, if a prostatectomy was not done), and Gleason histologic grade for the prostatectomy specimen (or biopsy specimen if a prostatectomy was not done) to stage the prostate cancer cases. Because cases with incidental microscopic focal tumors (T1a) are generally indolent and are more susceptible to detection bias due to differential rates of undergoing surgery for benign prostatic hyperplasia, we excluded these from our primary analysis. Because dietary fats have been reported to be more strongly related to metastatic prostate cancer than to incident prostate cancer (15), we considered total nonstage T1a prostate cancer, organ-confined prostate cancer, and advanced prostate cancer as separate prostate cancer endpoints. The latter were defined as cancers that were fatal by the end of follow-up or cancers extending regionally to the seminal vesicle, other adjacent organs, pelvic lymph nodes, or distal organs (usually bone) at the time of diagnosis.
Data analysis
Person-time of follow-up for each participant was calculated from the date of return of the 1986 questionnaire to the date of prostate cancer diagnosis, the date of death, or the end of the study period on 1 January 2000. For each fatty acid, the relative risk (RR) was calculated as the Mantel-Haenszel summary rate ratio of prostate cancer (16), with adjustment for age. Multivariate RRs were computed by using Cox proportional hazards regression (17). We used multivariate nutrient-density models because of their intuitive interpretation as a measure of dietary composition (18). The basic model included total energy intake; the percentages of energy derived from polyunsaturated fat, saturated fat, monounsaturated fat, trans fat, protein, and alcohol; and other potentially confounding variables. The coefficients from these models can be interpreted as the estimated effect of substituting a specific percentage of energy from a specific type of fat for the same percentage of energy from carbohydrates. To distinguish between individual polyunsaturates, we entered all major polyunsaturated fatty acids into the model simultaneously. Because intakes of EPA and DHA were highly correlated (r = 0.95) because of shared food sources, we entered the sum of EPA and DHA (EPA + DHA) into the model. We also examined EPA and DHA as separate variables unadjusted for each other.
In addition to these variables, the basic model included known or suspected risk factors for prostate cancer, such as family history of prostate cancer (yes or no), major ancestry (Scandinavian, Southern European, other Caucasian, and other ancestry), BMI at age 21 y (kg/m2, ordinal), height (inches, ordinal), history of type 2 diabetes mellitus (yes or no), history of vasectomy (yes or no), vigorous physical activity (yes or no), cigarette smoking in the past 10 y (yes or no), intakes of energy-adjusted lycopene (µg/d, ordinal), calcium (energy-adjusted from diet plus supplements, mg/d, ordinal), and supplemental vitamin E (yes or no). Tests of linear trend across increasing categories of fatty acid consumption were conducted by modeling the median values of quintiles of fatty acids as a continuous variable in the multivariate model.
We determined categories of exposure on the basis of cumulative average updating to compute the best assessment of average long-term fatty acid intake based on all available questionnaires and to allow for changes in fatty acid consumption over time. In this approach, we used the 1986 intakes to predict outcomes between 1986 and 1990, the average of the 1986 and the 1990 intakes to predict outcomes between 1990 and 1994, and the average of the 1986, 1990, and 1994 intakes to predict outcomes between 1994 and 2000. All hypothesis tests were two sided and were conducted by using SAS release 8.2 (SAS Institute, Cary, NC).
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
). ALA from nonanimal sources was positively correlated with LA (r = 0.66) but was not correlated with EPA (r = 0.07), DHA (r = 0.09), and AA (r = 0.09). LA showed weak inverse correlations with EPA (–0.12) and DHA (r = –0.11) and a weak positive correlation with AA (r = 0.12). The range of exposure varied 
3-fold between means of extreme quintiles of ALA from meat and dairy sources. The variation between means of extreme quintiles was 4-fold for ALA from nonanimal sources, >10-fold for EPA and DHA, 2-fold for LA, and 3-fold for AA.
|
). In general, men with higher intakes of ALA from meat and dairy sources smoked more but were less likely to undergo prostate-specific antigen (PSA) tests and be physically active, and they consumed less lycopene and fish than did men with low intakes of ALA from meat and dairy sources. In contrast, men with greater intakes of ALA from nonanimal sources and greater intakes of EPA and DHA smoked less, and they were more likely to undergo PSA tests and be physically active, and they consumed more lycopene, fish, and supplemental vitamin E than did men with low intakes of ALA from nonanimal sources and low intakes of EPA and DHA. No clear risk factor patterns were observed for LA and AA.
|
). No association was observed for intakes of total ALA, ALA from meat and dairy sources, and ALA from nonanimal sources. Intakes of EPA, DHA, and EPA + DHA showed a significant or borderline significant inverse relation with total prostate cancer. In contrast, LA and AA were unrelated to risk of total prostate cancer. The ratio of LA to ALA and the ratio of LA to EPA + DHA showed no association with total prostate cancer.
|
). There were only minor differences between the age-adjusted and multivariate RRs, suggesting no major confounding. In contrast to the results for total prostate cancer, intake of LA was positively associated with risk of organ-confined prostate cancer in age-adjusted analysis. However, the relation became statistically non-significant in multivariate analysis.
|
). For total ALA, ALA from meat and dairy sources, and ALA from nonanimal sources, the age-adjusted RRs for the comparison of extreme quintiles were 1.69 (95% CI: 1.26, 2.27), 1.29 (95% CI: 0.98, 1.70), and 1.39 (95% CI: 1.05, 1.85), respectively. After adjustment for potentially confounding variables, the RRs for comparisons of extreme quintiles of total ALA, ALA from meat and dairy sources, and ALA from nonanimal sources were 1.98 (95% CI: 1.34, 2.93), 1.53 (95% CI: 0.88, 2.66), and 2.02 (95% CI: 1.35, 3.03), respectively. Adjustment for LA accounted for most of the difference between the age-adjusted and multivariate findings. After further adjustment for red meat, the multivariate RR of advanced prostate cancer for comparisons of extreme quintiles of total ALA was 1.92 (95% CI: 1.29, 2.84; P for trend = 0.0002).
|
Fish-oil supplement use showed no relation with risk of prostate cancer. Compared with nonusers of fish-oil supplements, the multivariate RRs of total, organ-confined, and advanced prostate cancer for men at a dose of 2.5 g supplemental fish oil/d were 0.89 (95% CI: 0.62, 1.30; P for trend = 0.91), 0.81 (95% CI: 0.49, 1.33; P for trend = 0.44), and 0.91 (95% CI: 0.33, 2.55; P for trend = 0.80), respectively.
When ALA from individual food sources was examined, the risk of advanced prostate cancer with intake of ALA from meat and dairy sources appeared to increase more strongly among men with low intakes of ALA from nonanimal sources than among men with high intakes of ALA from nonanimal sources (Table 6). Similarly, the risk of advanced prostate cancer with intake of ALA from nonanimal sources was suggestively more pronounced among men with low intakes of ALA from meat and dairy sources than among those with high intakes of ALA from meat and dairy sources (P for interaction = 0.07). We also examined the combination of ALA and LA and the combination of ALA and EPA + DHA in relation to the risk of advanced prostate cancer. The relation of ALA to risk of advanced prostate cancer did not differ by level of LA intake (P for interaction = 0.49; Table 7), and it did not differ by level of EPA + DHA intake (P for interaction = 0.96; Table 8).
|
|
|
); these foods provided 41% of ALA intake at baseline. Most food items were unrelated or weakly positively related to risk of advanced prostate cancer. After adjustment for potentially confounding variables, increasing intakes of mayonnaise or other creamy salad dressings was the only food group that showed a statistically significant positive trend, although men (n = 15 cases) in the highest category had no increased risk. In age-adjusted analysis, intake of one or more servings per day of beef, pork, or lamb as a main dish was related to increased risk of advanced prostate cancer compared with intake at <1/mo. However, that relation became statistically nonsignificant in multivariate analysis.
|
To examine whether increased PSA screening among men with high intake of ALA from nonanimal sources and men with high intake of EPA + DHA may have accounted for the observed associations, we excluded all noncases who did not have a PSA test by 2000. The relations were essentially unaltered. The multivariate RRs of advanced prostate cancer for comparisons of extreme quintiles of total ALA, ALA from meat and dairy sources, and ALA from nonanimal sources were 1.99 (95% CI: 1.36, 2.94; P for trend = 0.0009), 1.61 (95% CI: 0.93, 2.81; P for trend = 0.049), and 2.06 (95% CI: 1.38, 3.08; P for trend = 0.0004), respectively. The multivariate RRs of total prostate cancer for comparisons of extreme quintiles of EPA, DHA, and EPA + DHA were 0.85 (95% CI: 0.74, 0.98; P for trend = 0.0005), 0.87 (95% CI: 0.75, 1.00; P for trend = 0.02), and 0.85 (95% CI: 0.73, 0.99; P for trend = 0.01), respectively. Similar results were observed when we limited the analysis to men who did not have a PSA test by 1994.
We also examined whether latent symptoms of prostate cancer may have caused a change in fatty acid consumption by repeating our analysis after excluding the first 4 y of follow-up and relating the 1986 fatty acid intake to incidence of prostate cancer from 1990 to 2000. The relations with EPA and DHA remained essentially unchanged. The multivariate RRs of total prostate cancer for comparisons of extreme quintiles of EPA, DHA, and EPA + DHA were 0.78 (95% CI: 0.67, 0.89; P for trend = 0.0002), 0.78 (95% CI: 0.67, 0.91; P for trend = 0.0003), and 0.86 (95% CI: 0.73, 1.00; P for trend = 0.01), respectively. The multivariate RR of advanced prostate cancer for comparisons of extreme quintiles of EPA + DHA was 0.65 (95% CI: 0.41, 1.01; P for trend = 0.08). In contrast, the associations with ALA were attenuated. The multivariate RRs of advanced prostate cancer for comparisons of extreme quintiles of total ALA, ALA from meat and dairy sources, and ALA from nonanimal sources were 1.41 (95% CI: 0.90, 2.19; P for trend = 0.08), 1.12 (95% CI: 0.58, 2.18; P for trend = 0.48), and 1.65 (95% CI: 1.02, 2.67; P for trend = 0.04), respectively.
The associations between intake of total ALA, ALA from meat and dairy sources, ALA from nonanimal sources, and EPA, DHA, EPA + DHA, LA, and AA and total, organ-confined, and advanced prostate cancer risk were not modified by each other or by other potential prostate cancer risk factors, such as time period, age, family history of prostate cancer, major ancestry, BMI, height, history of type 2 diabetes, history of vasectomy, vigorous physical activity, cigarette smoking in the previous decade, and intakes of total energy, lycopene, calcium, vitamin E, red meat, fish, and alcohol (all P for interaction > 0.05).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In contrast, 3 case-control studies (26-28), all of which examined advanced prostate cancer outcomes separately, observed no association between ALA intake and prostate cancer. Only 2 studies (29, 30) suggest a potential benefit of ALA on prostate cancer risk. One was a prospective study from the Netherlands (29) that found a decreased risk of total prostate cancer (P = 0.09) and no association between total linolenic acid intake and advanced prostate cancer. The range of linolenic acid intake in that study largely overlapped with that in our study. However, LA intake in the Dutch study was considerably higher than in our study. Because ALA and LA compete for key enzymes, such as 
6-desaturase, which is involved in parallel pathways for eicosanoid synthesis (31), low intakes of LA may further exaggerate the risk of prostate cancer related to ALA intake. Thus, one possible explanation for the disparate results between the Dutch study (29) and ours is that a high intake of LA alleviates the increased risk of prostate cancer associated with a high intake of ALA.
The other inverse study (30) found lower prostatic tissue concentrations of ALA in cases than in controls (P = 0.008). However, little is known about whether ALA concentrations in prostate cancer cases are altered by the malignancy (32). Circumstantial evidence suggests that ALA may differentially influence aggressive prostate cancer types and indolent types. An intervention study (33) using a flaxseed-supplemented diet in prostate cancer patients reported a suggestive decrease in PSA in men with Gleason sums of 
6 (P = 0.10), whereas a suggestive increase in PSA (P = 0.13) was observed in men with Gleason sums of 7. In our study, ALA was not associated with total or organ-confined prostate cancer, but it was positively related to risk of advanced prostate cancer.
The increased risk of advanced prostate cancer with ALA observed in the current study was within the range of adequate intake of 2.2 g/d, or 1% of energy, for adults recommended by the International Society for the Study of Fatty Acids and Lipids (34). The significance of a potentially adverse effect of ALA intake on prostate cancer risk is accentuated by a 40% increased availability of ALA as a proportion of total energy intake in recent decades in the United States (35). We were unable to identify individual foods responsible for an increased risk of advanced prostate cancer, although suggestive positive relations were observed for intakes of beef, pork, or lamb as a main dish and for mayonnaise or other creamy salad dressings. The most likely explanations for these findings are that most foods contribute only a fraction to overall ALA intake and that overall ALA intake rather than intake of any particular food item may be the main determinant of risk.
A high intake of EPA + DHA was associated or suggestively associated with a decreased risk of total and advanced prostate cancer. This finding is largely consistent with the findings of a recent analysis of fish consumption from our cohort (12), another prospective study (36), and 6 case-control studies (25, 37-41) that found decreased prostate cancer risk associated with high intakes of fish or marine n–3 fatty acids, all but one (41) of which were statistically significant. However, the results of 9 prospective studies (21, 24, 29, 42-47) and 4 case-control studies (23, 48-50) argue against a relation between marine fatty acids or fish and prostate cancer; one cohort study (51) reported a borderline statistically significant increased risk with greater fish intake. Our results for fish-oil supplement use were weaker than those for EPA + DHA from diet and supplements combined, which suggests that fish may contain additional protective agents not contained in fish-oil supplements, such as vitamin D and retinol.
A high LA intake was unrelated to the risk of prostate cancer. Previous investigations on LA and prostate cancer are mixed; 3 case-control studies observed a statistically significant (25) or nonsignificant (23, 27) positive association, 2 prospective studies (21, 29) and 3 case-control studies (22, 26, 42) reported no association, and one additional prospective study (24) and 3 case-control studies (19, 28, 52) observed a statistically significant (52) or nonsignificant (19, 24, 28) inverse relation. We, as did others (21-24, 29), observed no association with AA. Our null findings for LA and AA are in contrast with hypothetical biological mechanisms, which suggests that n–6 fatty acids enhance prostate tumor growth (6).
Our results of a decreased risk of advanced prostate cancer with increasing ratios of LA to ALA, the main n–6 and n–3 fatty acids in Western diets, agree with the results of 2 prospective studies (21, 24) that reported an inverse relation with prostate cancer. In contrast, the positive association we observed between the ratio of LA to EPA + DHA and advanced prostate cancer was not consistent with the finding in one study (21), which found a statistically nonsignificant inverse relation. Taken together, the sparse data available suggest that decreasing the overall ratio of n–6 to n–3 fatty acids does not favorably affect prostate cancer risk. However, because the risk estimates for the ratio of LA to ALA and of LA to EPA + DHA in relation to advanced prostate cancer were in opposite directions, evaluation of these fatty acids independently, rather than as ratios, is likely to be more informative.
Fatty acids may modulate prostate carcinogenesis through numerous processes, such as modification of membrane phospholipid composition (53), alteration of cell signaling and receptor activity (54-56), lipid peroxidation (57), cyclooxygenase inhibition (58), cytokine production (59), and interference with androgen activity (60). Experimental studies show that prostate tumor growth is inhibited by EPA and DHA (6, 61). In contrast, ALA shows no protective effect on prostate tumor growth in animal models (6, 61), and ALA can promote prostate cancer cell growth in vitro (62). Thus, laboratory studies of prostate carcinogenesis comparing the effects of ALA with those of EPA and DHA provide no evidence in support of a protective influence of ALA in its own right.
The specific mechanisms underlying why n–3 fatty acids mainly from terrestrial and those mainly from marine sources may have divergent effects on prostate cancer risk are unclear. One possibility is that ALA is less effective than are EPA and DHA in displacing AA from cell membrane phospholipids (63, 64) and in inhibiting prostaglandin synthesis (65). ALA conversion is limited for EPA (66) and severely constrained for DHA (67), particularly under conditions of adequate supply of preformed EPA and DHA (68). Increased dietary availability of ALA does not obligatorily enhance DHA synthesis and may even decrease tissue DHA concentrations (69) because DHA synthesis appears to be tightly regulated by feedback inhibition (70). Another possibility is that EPA and DHA have numerous antiinflammatory properties that have been linked with decreased cancer risk (71), whereas ALA shows little influence on immune function and inflammatory cytokine production at feasible dietary intakes (72).
In summary, our results suggest that a high ALA intake is associated with an increased risk of advanced prostate cancer. In contrast, high EPA and DHA intakes may be associated with a decreased risk of total and advanced prostate cancer. Because the apparent adverse effect of ALA on risk of advanced prostate cancer may counter the reduction in cardiovascular disease that may be achieved through ALA use (73), further research in men is imperative to resolve the relation of ALA to prostate cancer and to determine the risk-benefit tradeoffs associated with dietary intake of ALA (74).
|
ACKNOWLEDGMENTS |
|---|
MFL, MJS, DSM, KA, GCC, WCW, and ELG were responsible for the study concept and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and the statistical analysis. MJS, DSM, WCW, and ELG obtained the funding for the study. MJS, GCC, WCW, and ELG provided administrative, technical, or material support. None of the authors had any conflicts of interest in connection with this study.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  J. A Simon, Y.-H. Chen, and S. Bent The relation of {alpha}-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1558S - 1564S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Harris, D. Mozaffarian, M. Lefevre, C. D. Toner, J. Colombo, S. C. Cunnane, J. M. Holden, D. M. Klurfeld, M. C. Morris, and J. Whelan Towards Establishing Dietary Reference Intakes for Eicosapentaenoic and Docosahexaenoic Acids J. Nutr., April 1, 2009; 139(4): 804S - 819S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fradet, I. Cheng, G. Casey, and J. S. Witte Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk Clin. Cancer Res., April 1, 2009; 15(7): 2559 - 2566. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Daniel, M. L. McCullough, R. C. Patel, E. J. Jacobs, W. D. Flanders, M. J. Thun, and E. E. Calle Dietary Intake of {omega}-6 and {omega}-3 Fatty Acids and Risk of Colorectal Cancer in a Prospective Cohort of U.S. Men and Women Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 516 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Whelan Dietary Stearidonic Acid Is a Long Chain (n-3) Polyunsaturated Fatty Acid with Potential Health Benefits J. Nutr., January 1, 2009; 139(1): 5 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K Virtanen, D. Mozaffarian, S. E Chiuve, and E. B Rimm Fish consumption and risk of major chronic disease in men Am. J. Clinical Nutrition, December 1, 2008; 88(6): 1618 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Demark-Wahnefried, T. J. Polascik, S. L. George, B. R. Switzer, J. F. Madden, M. T. Ruffin IV, D. C. Snyder, K. Owzar, V. Hars, D. M. Albala, et al. Flaxseed Supplementation (Not Dietary Fat Restriction) Reduces Prostate Cancer Proliferation Rates in Men Presurgery Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3577 - 3587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E Chavarro, M. J Stampfer, M. N Hall, H. D Sesso, and J. Ma A 22-y prospective study of fish intake in relation to prostate cancer incidence and mortality Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1297 - 1303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W Turunen, P. K Verkasalo, H. Kiviranta, E. Pukkala, A. Jula, S. Mannisto, R. Rasanen, J. Marniemi, and T. Vartiainen Mortality in a cohort with high fish consumption Int. J. Epidemiol., October 1, 2008; 37(5): 1008 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McEntee, C. Ziegler, D. Reel, K. Tomer, A. Shoieb, M. Ray, X. Li, N. Neilsen, F. B. Lih, D. O'Rourke, et al. Dietary n-3 Polyunsaturated Fatty Acids Enhance Hormone Ablation Therapy in Androgen-Dependent Prostate Cancer Am. J. Pathol., July 1, 2008; 173(1): 229 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Edwards, H. Sun, Y. Hu, I. M. Berquin, J. T. O'Flaherty, J. M. Cline, L. L. Rudel, and Y. Q. Chen In Vivo and in Vitro Regulation of Syndecan 1 in Prostate Cells by n-3 Polyunsaturated Fatty Acids J. Biol. Chem., June 27, 2008; 283(26): 18441 - 18449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R J. Barnard Prostate cancer prevention by nutritional means to alleviate metabolic syndrome Am. J. Clinical Nutrition, September 1, 2007; 86(3): 889S - 893S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Simon, J. S. Tanzman, and J. Sabate Lack of Effect of Walnuts on Serum Levels of Prostate Specific Antigen: A Brief Report J. Am. Coll. Nutr., August 1, 2007; 26(4): 317 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Chavarro, M. J. Stampfer, H. Li, H. Campos, T. Kurth, and J. Ma A Prospective Study of Polyunsaturated Fatty Acid Levels in Blood and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Neuhouser, M. J. Barnett, A. R. Kristal, C. B. Ambrosone, I. King, M. Thornquist, and G. Goodman (n-6) PUFA Increase and Dairy Foods Decrease Prostate Cancer Risk in Heavy Smokers J. Nutr., July 1, 2007; 137(7): 1821 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lee, K. M. Gura, S. Kim, D. A. Arsenault, B. R. Bistrian, and M. Puder Current Clinical Applications of {Omega}-6 and {Omega}-3 Fatty Acids Nutr Clin Pract, August 1, 2006; 21(4): 323 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kobayashi, R. J. Barnard, S. M. Henning, D. Elashoff, S. T. Reddy, P. Cohen, P. Leung, J. Hong-Gonzalez, S. J. Freedland, J. Said, et al. Effect of Altering Dietary {omega}-6/{omega}-3 Fatty Acid Ratios on Prostate Cancer Membrane Composition, Cyclooxygenase-2, and Prostaglandin E2 Clin. Cancer Res., August 1, 2006; 12(15): 4662 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kamangar, G. M. Dores, and W. F. Anderson Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World J. Clin. Oncol., May 10, 2006; 24(14): 2137 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. MacLean, S. J. Newberry, W. A. Mojica, P. Khanna, A. M. Issa, M. J. Suttorp, Y.-W. Lim, S. B. Traina, L. Hilton, R. Garland, et al. Effects of Omega-3 Fatty Acids on Cancer Risk: A Systematic Review JAMA, January 25, 2006; 295(4): 403 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Fritsche Are Omega-3 Fatty Acids Effective in Enhancing Tumoricidal Cell Activity? J. Nutr., December 1, 2005; 135(12): 2916S - 2917S. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tonon, R. Qing, D. Harvey, Y. Li, T. R. Larson, and I. A. Graham Identification of a Long-Chain Polyunsaturated Fatty Acid Acyl-Coenzyme A Synthetase from the Diatom Thalassiosira pseudonana Plant Physiology, May 1, 2005; 138(1): 402 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Lorgeril and P. Salen {alpha}-Linolenic Acid, Coronary Heart Disease, and Prostate Cancer J. Nutr., December 1, 2004; 134(12): 3385 - 3385. [Full Text] [PDF]
|
|
|
|
|
|
I. A. Brouwer, M. B. Katan, and P. L. Zock Reply to de Lorgeril and Salen J. Nutr., December 1, 2004; 134(12): 3386 - 3386. [Full Text] [PDF]
|
|
|
|
|
|
P. D. Terry, J. B. Terry, and T. E. Rohan Long-Chain (n-3) Fatty Acid Intake and Risk of Cancers of the Breast and the Prostate: Recent Epidemiological Studies, Biological Mechanisms, and Directions for Future Research J. Nutr., December 1, 2004; 134(12): 3412S - 3420S. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
